<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:0183ba30-05b1-4e10-9cd4-ff27ba09442d,g:cc347450-56f2-4506-828b-09d401c9f0dd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_50d3390d-ac72-4e43-9256-03373b1625d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_50d3390d-ac72-4e43-9256-03373b1625d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2c23a3a7-b9bc-4785-9d72-d8db6965c35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2c23a3a7-b9bc-4785-9d72-d8db6965c35f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0ac49d54-1ef2-460f-980e-a439d1aeccb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0ac49d54-1ef2-460f-980e-a439d1aeccb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9795a2d1-8a3b-4ff3-ab6b-50886b0c49af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:to="loc_us-gaap_InventoryNet_9795a2d1-8a3b-4ff3-ab6b-50886b0c49af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cef4981-d9d6-4d0b-98ff-fdbd506fe074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3af66454-7b3c-4c6d-89dc-d542ebfde9f4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6cef4981-d9d6-4d0b-98ff-fdbd506fe074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7ea4216a-d15b-4153-8e6b-d4da8693316b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_4e391827-aac4-4452-ac5b-8ddac4c71685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7ea4216a-d15b-4153-8e6b-d4da8693316b" xlink:to="loc_us-gaap_CommonStockValueOutstanding_4e391827-aac4-4452-ac5b-8ddac4c71685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bb3d190-0377-46e3-bc48-6834b4fe1547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7ea4216a-d15b-4153-8e6b-d4da8693316b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bb3d190-0377-46e3-bc48-6834b4fe1547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6ef9ec3-bebc-46a9-90b1-4429f40c8d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f47eb42f-fd5a-45ce-ba11-f1cde4ce0a22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6ef9ec3-bebc-46a9-90b1-4429f40c8d14" xlink:to="loc_us-gaap_Liabilities_f47eb42f-fd5a-45ce-ba11-f1cde4ce0a22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_caf482e3-c00f-415f-af35-283eea5fd2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6ef9ec3-bebc-46a9-90b1-4429f40c8d14" xlink:to="loc_us-gaap_CommitmentsAndContingencies_caf482e3-c00f-415f-af35-283eea5fd2a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b205986d-60a7-4dec-a863-4ac6ac500973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6ef9ec3-bebc-46a9-90b1-4429f40c8d14" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b205986d-60a7-4dec-a863-4ac6ac500973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_899821ef-5de6-4779-a7bb-ad46dd0f9df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d9886f72-7349-4ea7-8ff8-9e41ac04dfcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_899821ef-5de6-4779-a7bb-ad46dd0f9df6" xlink:to="loc_us-gaap_StockholdersEquity_d9886f72-7349-4ea7-8ff8-9e41ac04dfcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8f935e5d-3428-4c89-a8b6-8e5916dd2912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_899821ef-5de6-4779-a7bb-ad46dd0f9df6" xlink:to="loc_us-gaap_MinorityInterest_8f935e5d-3428-4c89-a8b6-8e5916dd2912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9ed2bd6a-fae2-4439-9ef6-146473c58be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9e71f291-e8a3-488a-82c8-87e9a74e095e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ed2bd6a-fae2-4439-9ef6-146473c58be4" xlink:to="loc_us-gaap_AccountsPayableCurrent_9e71f291-e8a3-488a-82c8-87e9a74e095e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6b19c0d7-8c2c-4eb8-83e3-c61769c465d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ed2bd6a-fae2-4439-9ef6-146473c58be4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6b19c0d7-8c2c-4eb8-83e3-c61769c465d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_8a7bebea-438d-4ca7-ad15-7b2596c2fd86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ed2bd6a-fae2-4439-9ef6-146473c58be4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_8a7bebea-438d-4ca7-ad15-7b2596c2fd86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_32cbd5f1-a4af-4762-8318-1fa964aa9988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ed2bd6a-fae2-4439-9ef6-146473c58be4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_32cbd5f1-a4af-4762-8318-1fa964aa9988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1a943fae-6759-4db9-86a4-a4e64c317ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_AssetsCurrent_1a943fae-6759-4db9-86a4-a4e64c317ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_63ff18bc-1a3f-4743-87a4-a7415fe05695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_63ff18bc-1a3f-4743-87a4-a7415fe05695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_96462b43-8243-40db-8f56-eeaa52903313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_96462b43-8243-40db-8f56-eeaa52903313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8a620dbb-e8d9-413f-bd1c-0936f52d2660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_Goodwill_8a620dbb-e8d9-413f-bd1c-0936f52d2660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7d2c5939-a7fb-4f65-8399-3a4ab89e6d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7d2c5939-a7fb-4f65-8399-3a4ab89e6d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3c960195-76ec-40f2-b23b-22d389bd9e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3c960195-76ec-40f2-b23b-22d389bd9e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_308475a8-d07e-4ca8-bdcb-41d44f1a08a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_InventoryNoncurrent_308475a8-d07e-4ca8-bdcb-41d44f1a08a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f612e500-c4c4-48ae-8713-0696ba570c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ff73797e-6afa-45b3-9d3a-c6bfc1bbbd6b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f612e500-c4c4-48ae-8713-0696ba570c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6179d3af-ffd2-40d4-8bf9-fd138bb7d1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_44667b02-1db0-4075-807e-607cec33af8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6179d3af-ffd2-40d4-8bf9-fd138bb7d1ba" xlink:to="loc_us-gaap_LiabilitiesCurrent_44667b02-1db0-4075-807e-607cec33af8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_6ce7c9eb-1f74-482c-9fce-9a8119e21506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6179d3af-ffd2-40d4-8bf9-fd138bb7d1ba" xlink:to="loc_us-gaap_LongTermLineOfCredit_6ce7c9eb-1f74-482c-9fce-9a8119e21506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4bd9eb4c-5945-41c3-9bbe-b71edf1dcdb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6179d3af-ffd2-40d4-8bf9-fd138bb7d1ba" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4bd9eb4c-5945-41c3-9bbe-b71edf1dcdb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_deb1a007-76d5-44d3-84c1-b06e08618db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6179d3af-ffd2-40d4-8bf9-fd138bb7d1ba" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_deb1a007-76d5-44d3-84c1-b06e08618db8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofIncomeandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_204beb65-f935-4ea1-a54b-fd2ba862a9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0b70065a-d3f5-46c9-8237-0e0c0340e459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_204beb65-f935-4ea1-a54b-fd2ba862a9fe" xlink:to="loc_us-gaap_ProfitLoss_0b70065a-d3f5-46c9-8237-0e0c0340e459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_12f1ba4f-479d-4ece-996c-d9025ebbd7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_204beb65-f935-4ea1-a54b-fd2ba862a9fe" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_12f1ba4f-479d-4ece-996c-d9025ebbd7fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e830e48-5e5f-4129-a5ab-dcd4cf96ebb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4c9f6aeb-ecf8-403b-aeba-9bb3a9095b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e830e48-5e5f-4129-a5ab-dcd4cf96ebb5" xlink:to="loc_us-gaap_OperatingIncomeLoss_4c9f6aeb-ecf8-403b-aeba-9bb3a9095b91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_572d0ac1-ddbd-4b03-af2d-e0ff4360f335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e830e48-5e5f-4129-a5ab-dcd4cf96ebb5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_572d0ac1-ddbd-4b03-af2d-e0ff4360f335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_20879b4a-cd31-4c17-8bf8-b5dcd9763889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9e830e48-5e5f-4129-a5ab-dcd4cf96ebb5" xlink:to="loc_us-gaap_InterestExpense_20879b4a-cd31-4c17-8bf8-b5dcd9763889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a5e5acf1-f41f-4430-b528-a3d246878062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a5e5acf1-f41f-4430-b528-a3d246878062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_06383d05-7a7a-4546-8747-20c7cd499725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:to="loc_us-gaap_SellingAndMarketingExpense_06383d05-7a7a-4546-8747-20c7cd499725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b9db91b3-de1c-427f-aef2-5ca8ac067e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b9db91b3-de1c-427f-aef2-5ca8ac067e04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_93c053c3-c4ad-4349-84a8-8496893b540e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_93c053c3-c4ad-4349-84a8-8496893b540e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c80fc06f-85ed-4f9d-b324-010a3de4141b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_49dfdb53-f8da-4447-baf0-e484f72c855e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c80fc06f-85ed-4f9d-b324-010a3de4141b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5a8086ee-9c01-4795-84ad-1046a455486d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_eec9622d-7bda-4376-8b29-1ce83dfa21fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5a8086ee-9c01-4795-84ad-1046a455486d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_eec9622d-7bda-4376-8b29-1ce83dfa21fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_328e41af-4392-4aab-ac60-14bfd5df8376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5a8086ee-9c01-4795-84ad-1046a455486d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_328e41af-4392-4aab-ac60-14bfd5df8376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d281723b-126c-457f-b3d3-77cc34d034b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a0e4c2f3-5ef8-4759-9159-2a76e1ce837e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d281723b-126c-457f-b3d3-77cc34d034b7" xlink:to="loc_us-gaap_CostsAndExpenses_a0e4c2f3-5ef8-4759-9159-2a76e1ce837e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e031b9b4-5519-4023-9cb5-f0d399f50858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d281723b-126c-457f-b3d3-77cc34d034b7" xlink:to="loc_us-gaap_Revenues_e031b9b4-5519-4023-9cb5-f0d399f50858" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_187651d9-1375-4d78-82ff-70823e485294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2da3fb36-857e-48d6-b71c-85c7e014ab2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_187651d9-1375-4d78-82ff-70823e485294" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2da3fb36-857e-48d6-b71c-85c7e014ab2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b970633-3f36-4087-81c5-8d8b6a46c470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_187651d9-1375-4d78-82ff-70823e485294" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b970633-3f36-4087-81c5-8d8b6a46c470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d368be76-d54e-4d14-a408-b22ba9938270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_187651d9-1375-4d78-82ff-70823e485294" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d368be76-d54e-4d14-a408-b22ba9938270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_22b0f166-da34-4546-8a51-5a56dd834156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_22b0f166-da34-4546-8a51-5a56dd834156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0c021b31-7952-4822-b6a7-c9e526065d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0c021b31-7952-4822-b6a7-c9e526065d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_26ddba9d-48b0-44c0-abb6-2b52a58bc4ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_26ddba9d-48b0-44c0-abb6-2b52a58bc4ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bd9820f3-cf09-44f0-bad6-906df4f10a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bd9820f3-cf09-44f0-bad6-906df4f10a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_01425d2b-3744-49a5-881e-8808c9808e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_01425d2b-3744-49a5-881e-8808c9808e7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_cfa3b159-efb5-4f84-8270-363f08aadd82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_cfa3b159-efb5-4f84-8270-363f08aadd82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_5cd24e3f-ea1d-4287-9159-0dd5b81a29e8" xlink:href="cpix-20201231.xsd#cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d540fe4-9740-490f-86eb-a34743adaa51" xlink:to="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_5cd24e3f-ea1d-4287-9159-0dd5b81a29e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e4b8eeff-051a-469a-9316-9ea03c7ff4b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e4b8eeff-051a-469a-9316-9ea03c7ff4b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_679f293d-4880-4ad5-a217-2dfb06bb0696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_679f293d-4880-4ad5-a217-2dfb06bb0696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_7050053e-401f-482f-9b9a-e3e9b7c9af79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_7050053e-401f-482f-9b9a-e3e9b7c9af79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_3691f812-6a8c-47a0-90bf-d8af4d05ad1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_3691f812-6a8c-47a0-90bf-d8af4d05ad1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_36ad37e5-b751-4982-80a5-731a61e9d58f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_36ad37e5-b751-4982-80a5-731a61e9d58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_6716562a-745b-49a2-aa45-e3f60ef20cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_6716562a-745b-49a2-aa45-e3f60ef20cc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7febacfd-c383-48c0-a231-9e0b08609f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7febacfd-c383-48c0-a231-9e0b08609f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f340a796-fc0d-4b36-ba10-617aa5e7f9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f340a796-fc0d-4b36-ba10-617aa5e7f9e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_6fed93d1-5e7d-443c-91e5-005057274450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff5c6af4-02a2-4907-a20d-99129e6addc7" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_6fed93d1-5e7d-443c-91e5-005057274450" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20201231.xsd#ConsolidatedStatementsofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Organization" xlink:type="simple" xlink:href="cpix-20201231.xsd#Organization"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Organization" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#OrganizationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativ" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativ"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativ" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativVibativAcquisitionNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexandVibativVibativAcquisitionScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_7041f034-9419-4161-871b-77b905fadeaa" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_43e328e3-b167-4b44-a72e-3134c0a82c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_7041f034-9419-4161-871b-77b905fadeaa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_43e328e3-b167-4b44-a72e-3134c0a82c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8bc64ec2-829a-411c-8e56-6acb0f97541e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_7041f034-9419-4161-871b-77b905fadeaa" xlink:to="loc_us-gaap_Goodwill_8bc64ec2-829a-411c-8e56-6acb0f97541e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4beb647-2d6a-4f5d-9c31-0a168b9b1e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6a3d5f76-556b-492f-ab33-4e74a01baf15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4beb647-2d6a-4f5d-9c31-0a168b9b1e74" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6a3d5f76-556b-492f-ab33-4e74a01baf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5167ee1b-3e4d-4f97-bdcd-211686612ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4beb647-2d6a-4f5d-9c31-0a168b9b1e74" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5167ee1b-3e4d-4f97-bdcd-211686612ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_998a923a-88eb-451c-98f7-c6aa2efdcb7f" xlink:href="cpix-20201231.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4beb647-2d6a-4f5d-9c31-0a168b9b1e74" xlink:to="loc_cpix_PaymentsForContingentConsideration_998a923a-88eb-451c-98f7-c6aa2efdcb7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3c40a46a-6e82-48ef-bb2e-caed9af1d02d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_31ef310e-8019-41cd-8905-b6a8c8e8932d" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3c40a46a-6e82-48ef-bb2e-caed9af1d02d" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_31ef310e-8019-41cd-8905-b6a8c8e8932d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_afc321e0-21d1-4404-8b19-b09e70d567ca" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3c40a46a-6e82-48ef-bb2e-caed9af1d02d" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_afc321e0-21d1-4404-8b19-b09e70d567ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_2d67a76b-737f-4deb-a51d-0ade6f4f591f" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3c40a46a-6e82-48ef-bb2e-caed9af1d02d" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_2d67a76b-737f-4deb-a51d-0ade6f4f591f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_ebba79cc-547c-4cc4-8352-ab367ce74cf7" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3c40a46a-6e82-48ef-bb2e-caed9af1d02d" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_ebba79cc-547c-4cc4-8352-ab367ce74cf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da34e6c8-f442-4e38-91b1-d70c5ac2f7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_21156942-2696-4890-99ac-5321b1182d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da34e6c8-f442-4e38-91b1-d70c5ac2f7ff" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_21156942-2696-4890-99ac-5321b1182d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_e7865a1e-61c7-4551-a94a-fe604eff1f12" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da34e6c8-f442-4e38-91b1-d70c5ac2f7ff" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_e7865a1e-61c7-4551-a94a-fe604eff1f12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20201231.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20201231.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ca2c54ec-b264-4fc4-bba6-3dcae5272850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_7d655ad3-a3e7-4440-ad81-b3bd728a95a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ca2c54ec-b264-4fc4-bba6-3dcae5272850" xlink:to="loc_us-gaap_InventoryGross_7d655ad3-a3e7-4440-ad81-b3bd728a95a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_6bbf7a4e-0d8d-452e-978a-74313d27232f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ca2c54ec-b264-4fc4-bba6-3dcae5272850" xlink:to="loc_us-gaap_InventoryNoncurrent_6bbf7a4e-0d8d-452e-978a-74313d27232f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_54aac9ab-cbcc-42ac-8f07-ecf0d8a19958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a8e287a7-6598-4784-9560-0d42aef7696e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_54aac9ab-cbcc-42ac-8f07-ecf0d8a19958" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a8e287a7-6598-4784-9560-0d42aef7696e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_67503536-5499-433a-9794-d296e62ca929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_54aac9ab-cbcc-42ac-8f07-ecf0d8a19958" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_67503536-5499-433a-9794-d296e62ca929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_da02d0da-4f3c-4fee-8de7-d91f9d91b7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_54aac9ab-cbcc-42ac-8f07-ecf0d8a19958" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_da02d0da-4f3c-4fee-8de7-d91f9d91b7ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_80aa239c-fe3e-4afb-842c-06bd6bb4ccc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_89d8deca-7f4f-46a1-afce-cd9f45919b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_80aa239c-fe3e-4afb-842c-06bd6bb4ccc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_89d8deca-7f4f-46a1-afce-cd9f45919b58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5385f80a-46df-44f8-b8e9-dc63b5818474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_80aa239c-fe3e-4afb-842c-06bd6bb4ccc5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5385f80a-46df-44f8-b8e9-dc63b5818474" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ab0c5255-5f69-4154-b20c-2a23deec2360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bd1cccf5-1380-43c6-a72f-7829385f1ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ab0c5255-5f69-4154-b20c-2a23deec2360" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bd1cccf5-1380-43c6-a72f-7829385f1ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4bf8bbcf-13f3-416a-813a-099912fb6d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ab0c5255-5f69-4154-b20c-2a23deec2360" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4bf8bbcf-13f3-416a-813a-099912fb6d28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3040394e-e5ab-428e-a365-5a0ad5f59dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3040394e-e5ab-428e-a365-5a0ad5f59dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9fb16f7c-2af3-46fd-858a-7a3e12ccfa68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9fb16f7c-2af3-46fd-858a-7a3e12ccfa68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9b255d77-4d23-49fd-aab1-a51eede7d417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9b255d77-4d23-49fd-aab1-a51eede7d417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d60f64a4-52b2-4d44-a1e6-09e53b74e973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d60f64a4-52b2-4d44-a1e6-09e53b74e973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_4e809626-f62f-42f4-afba-dced5dd97e58" xlink:href="cpix-20201231.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c5c41e2c-b329-41cd-a4a5-903e4f1ab7f0" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_4e809626-f62f-42f4-afba-dced5dd97e58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilities"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentandNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_dd26c8c8-1c53-41bb-a014-6b9ee9a16525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cb783b2a-44ad-4fdd-8e86-d421706c9a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_dd26c8c8-1c53-41bb-a014-6b9ee9a16525" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cb783b2a-44ad-4fdd-8e86-d421706c9a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1b440805-3cd8-4e3c-af06-7661144c1fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_dd26c8c8-1c53-41bb-a014-6b9ee9a16525" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1b440805-3cd8-4e3c-af06-7661144c1fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_d986ec68-a140-4525-b6c5-9dc78436e8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_dd26c8c8-1c53-41bb-a014-6b9ee9a16525" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_d986ec68-a140-4525-b6c5-9dc78436e8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_bfe2e5e3-3481-462c-81f9-2f238630b8e5" xlink:href="cpix-20201231.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_bfe2e5e3-3481-462c-81f9-2f238630b8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_52b587fd-52de-4648-a9e9-5c5c51547e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_52b587fd-52de-4648-a9e9-5c5c51547e43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_5a947476-473f-40eb-9661-ab99e2b1f90f" xlink:href="cpix-20201231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_5a947476-473f-40eb-9661-ab99e2b1f90f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredAcquisitionLiabilityCurrent_c6befacf-c31c-4f4f-b613-c1f373e8c031" xlink:href="cpix-20201231.xsd#cpix_DeferredAcquisitionLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_cpix_DeferredAcquisitionLiabilityCurrent_c6befacf-c31c-4f4f-b613-c1f373e8c031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases_be71fcfe-a652-4280-b73b-bed9695b774a" xlink:href="cpix-20201231.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_cpix_AccruedLiabilitiesInventoryPurchases_be71fcfe-a652-4280-b73b-bed9695b774a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_84663d77-5467-43fb-8df4-48a1e9301b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_84663d77-5467-43fb-8df4-48a1e9301b9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedPaymentForAssetPurchaseCurrent_087bb988-8f7e-415f-9fab-1897e7adff58" xlink:href="cpix-20201231.xsd#cpix_AccruedPaymentForAssetPurchaseCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_c3dc71eb-4628-423f-b7a6-ff0e7064c964" xlink:to="loc_cpix_AccruedPaymentForAssetPurchaseCurrent_087bb988-8f7e-415f-9fab-1897e7adff58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Debt" xlink:type="simple" xlink:href="cpix-20201231.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DebtLineofCreditDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityWarrantsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityWarrantsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9517faa3-9892-4dba-8fb7-9c2cc2a3a50c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_41ec51ec-64e0-4cde-8e27-14947848a49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9517faa3-9892-4dba-8fb7-9c2cc2a3a50c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_41ec51ec-64e0-4cde-8e27-14947848a49c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d0355ecb-70bd-4956-8a63-96442953ef41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9517faa3-9892-4dba-8fb7-9c2cc2a3a50c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d0355ecb-70bd-4956-8a63-96442953ef41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesOperatingLossCarryforwardsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesOperatingLossCarryforwardsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_0347362b-1f61-4a79-a45d-b288943e4b2b" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_0347362b-1f61-4a79-a45d-b288943e4b2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_39f52234-6ced-4f76-a83a-f67af67389d7" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_39f52234-6ced-4f76-a83a-f67af67389d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_c16808cc-bec7-4ffb-b8ba-cc9771c59f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_c16808cc-bec7-4ffb-b8ba-cc9771c59f65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_002399b2-b65f-4b0e-9318-7718547d298a" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_002399b2-b65f-4b0e-9318-7718547d298a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_f0775d4a-79cd-4b19-98c4-570d9cd1012c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_f0775d4a-79cd-4b19-98c4-570d9cd1012c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges_1e27218a-164f-4594-a995-b0ec619fdcc7" xlink:href="cpix-20201231.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_cpix_DeferredTaxAssetsDeferredCharges_1e27218a-164f-4594-a995-b0ec619fdcc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87b37c21-84e0-47ec-8d43-33265fecb12c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8c9f94-a3d3-470b-8d63-0aff8eb940f9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_87b37c21-84e0-47ec-8d43-33265fecb12c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_be3a1742-1663-4013-867a-20d92004e96d" xlink:href="cpix-20201231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_06e08a79-9d05-42b5-be57-ed1b32f13061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_be3a1742-1663-4013-867a-20d92004e96d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_06e08a79-9d05-42b5-be57-ed1b32f13061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9a110f43-2642-4e5b-8fd8-64873db4ad28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_be3a1742-1663-4013-867a-20d92004e96d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9a110f43-2642-4e5b-8fd8-64873db4ad28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dc9f776c-8eee-4322-8375-0dc0e8a298c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_f15eb1e6-31ef-447c-8240-eadf5cadc2ca" xlink:href="cpix-20201231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dc9f776c-8eee-4322-8375-0dc0e8a298c5" xlink:to="loc_cpix_NetDeferredTaxAssetsGross_f15eb1e6-31ef-447c-8240-eadf5cadc2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fe54ddc8-7c4a-4a21-8058-3affe4fb7df2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_dc9f776c-8eee-4322-8375-0dc0e8a298c5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fe54ddc8-7c4a-4a21-8058-3affe4fb7df2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5d77a9ef-5d24-477c-806a-682f2bfabea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_46165f65-f664-434e-97b8-6a52a64fa1af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5d77a9ef-5d24-477c-806a-682f2bfabea0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_46165f65-f664-434e-97b8-6a52a64fa1af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4c0db189-4a07-49b6-b77a-7a65d6e6b4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5d77a9ef-5d24-477c-806a-682f2bfabea0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4c0db189-4a07-49b6-b77a-7a65d6e6b4a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bcd9ddf8-2359-43c8-88e9-b7253ad12a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_65b44545-5501-4602-85cb-5dcca28357c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bcd9ddf8-2359-43c8-88e9-b7253ad12a5c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_65b44545-5501-4602-85cb-5dcca28357c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_9062ecab-ff9e-49bd-938c-8bb79df4b728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bcd9ddf8-2359-43c8-88e9-b7253ad12a5c" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_9062ecab-ff9e-49bd-938c-8bb79df4b728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_042d6a9f-bbfd-4809-a0f7-195307c52882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_058407e9-755e-4ccd-93b3-5b1ea43c198c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_042d6a9f-bbfd-4809-a0f7-195307c52882" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_058407e9-755e-4ccd-93b3-5b1ea43c198c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_faaf2bf4-69ce-4a98-9c54-3ff8d07d486c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_042d6a9f-bbfd-4809-a0f7-195307c52882" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_faaf2bf4-69ce-4a98-9c54-3ff8d07d486c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f80eb1d8-529b-49b8-b099-155fa1fdfe4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f80eb1d8-529b-49b8-b099-155fa1fdfe4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dfb0a886-15e0-4300-84e0-57f949ca9610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dfb0a886-15e0-4300-84e0-57f949ca9610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_003b4ebd-53bc-49c5-a9cd-12dcac996cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_003b4ebd-53bc-49c5-a9cd-12dcac996cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_55efc703-e413-4ece-bc2f-b9e1cf579984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_55efc703-e413-4ece-bc2f-b9e1cf579984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_fe6b01de-e242-44cd-a2ee-d78e3c28aabc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_fe6b01de-e242-44cd-a2ee-d78e3c28aabc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73edc1b5-f60f-4dc9-b7c5-dd6d3949ab81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d0a24e16-502c-4891-b26e-9cd1bf2c7516" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_73edc1b5-f60f-4dc9-b7c5-dd6d3949ab81" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlans"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofStockOptionsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofStockOptionsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmployeeBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmployeeBenefitPlansDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_05fead1d-d974-4447-99e4-498c03bd5cd1" xlink:href="cpix-20201231.xsd#cpix_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_40aa5226-6e20-4910-aa46-9c6e1bb9317e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_LeaseLiability_05fead1d-d974-4447-99e4-498c03bd5cd1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_40aa5226-6e20-4910-aa46-9c6e1bb9317e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a3d9acc2-21a1-493a-bbe7-d53e38330922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_LeaseLiability_05fead1d-d974-4447-99e4-498c03bd5cd1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a3d9acc2-21a1-493a-bbe7-d53e38330922" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76e6b7a1-cd59-49ff-b057-29fdfbfe6a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a1c1ced5-a161-4fb4-a318-d686f602cb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76e6b7a1-cd59-49ff-b057-29fdfbfe6a95" xlink:to="loc_us-gaap_OperatingLeaseLiability_a1c1ced5-a161-4fb4-a318-d686f602cb53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5ff0ac6c-2262-422e-9a46-a1ef86860483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_76e6b7a1-cd59-49ff-b057-29fdfbfe6a95" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5ff0ac6c-2262-422e-9a46-a1ef86860483" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/FairValueofFinancialInstrumentsScheduleofFairValueofFinancialInstrumentsbyLevelinHierarchyandNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrationsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="simple" xlink:href="cpix-20201231.xsd#ManufacturingandSupplyAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="simple" xlink:href="cpix-20201231.xsd#EmploymentAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#DiscontinuedOperationsDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d628ac11-9a0a-4a14-9b81-e709338d0da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_82624170-908c-479f-bcfa-3028fb2c9983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d628ac11-9a0a-4a14-9b81-e709338d0da5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_82624170-908c-479f-bcfa-3028fb2c9983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_899d17bd-ed6b-4800-8a24-244296823c50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d628ac11-9a0a-4a14-9b81-e709338d0da5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_899d17bd-ed6b-4800-8a24-244296823c50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="cpix-20201231.xsd#ValuationandQualifyingAccounts"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20201231.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended"/>
</link:linkbase>
